PI3.F Gubra A/S
- Market cap
- EUR 653M
- P/E
- -
- P/B
- 4.69x
- ROE
- 147.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is PI3.F undervalued?
Graham numberThe Graham number of Gubra A/S cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gubra A/S fundamental analysis
No fundamental analysis for Gubra A/S yet.
Gubra A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharma…
Full company profileGubra A/S financial statements
Gubra A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 255M | 199M | 205M | 266M | 2.64B |
| Gross Profit | 166M | 97.7M | 115M | 165M | 2.56B |
| Operating Income | 88.7M | -1.29M | -47.7M | -50.0M | 2.15B |
| EBITDA | - | 14.7M | -28.1M | -20.1M | 2.18B |
| Net Income | 67.9M | 4.31M | -44.5M | -36.5M | 1.69B |
| EPS | 4.16 | 0.26 | -2.73 | -2.24 | 104 |
| Balance Sheet | |||||
| Total Assets | 302M | 263M | 625M | 612M | 1.32B |
| Total Liabilities | 151M | 155M | 146M | 162M | 174M |
| Shareholders' Equity | 151M | 108M | 480M | 451M | 1.15B |
| Cash & Short-term Investments | 116M | 71.9M | 53.4M | 134M | 32.2M |
| Cash Flow | |||||
| Operating Cash Flow | 88.5M | 24.3M | -49.4M | 5.02M | 1.71B |
| Capital Expenditure | 27.2M | 14.2M | 11.2M | 32.1M | 19.2M |
| Free Cash Flow | 61.3M | 10.2M | -60.6M | -27.1M | 1.69B |
| Ratios | |||||
| ROE | 44.9% | 4.0% | -9.3% | -8.1% | 147.5% |
| ROA | 22.5% | 1.6% | -7.1% | -6.0% | 128.1% |
| Net Profit Margin | 26.6% | 2.2% | -21.7% | -13.7% | 64.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Gubra A/S dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 59.2%
- Ex-dividend date
- Jun 30, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | DKK 1.00B | 61 | 59.2% |
| 2024 | - | - | - |
| 2023 | DKK 68.3M | 4.19 | - |
| 2022 | DKK 66.0M | 4.04 | 1,531.6% |
| 2021 | DKK 6.63M | 0.41 | 9.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Gubra A/S
- Insiders 58.23%
- Institutions 12.40%
- Public & others 29.38%
- Shares outstanding 16.4M
- Free float 6.81M
Gubra A/S company profile
- Company name
- Gubra A/S
- Ticker
- PI3.F
- ISIN
- DK0062266474
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 330
- Fiscal year end
- December
- Address
- HOersholm Kongevej 11B, Horsholm, Denmark, 2970
- Phone
- 45 31 52 26 50
- Website
- gubra.dk
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology. It also has a portfolio strategy of potential drug candidates in the form of upfront payments, research payments, milestone payments, and royalties; and investments targeting as sets promoting the green transition. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Camurus' FluidCrystal technology to develop a therapy for hypoparathyroidism; Amylyx Pharmaceuticals to develop a GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is headquartered in Horsholm, Denmark.
Gubra A/S management
10- Mr. Markus Rohrwild Ph.D.Chief Executive Officer · born 1967
- Mr. Jacob JelsingCo-Founder & Director · born 1974
- Dr. Niels Vrang M.D., Ph.D.Co-founder & Director · born 1968
- Mr. Kristian BorbosChief Financial Officer · born 1978
- Ms. Line Holten ReimerChief Investment Officer
- Mr. Grigo GauravChief Technology Officer
- Louise Schjellerup DalbogeChief Science Officer
- Mr. Adam LangeHead of Investor Relations
- Ms. Lena Moran-Adams L.L.B.Group General Counsel
- Ms. Trine Nygaard HamannHead of Gubra CRO · born 1978